Ceritinib in ALK-rearranged non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  New England Journal of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMc1404894PMID 24963575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Acquired resistance to crizotinib from a mutation in CD74-ROS1.

  2013cited by this paper
• Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

  2013cited by this paper
• Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

  2012cited by this paper
• Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

  2012cited by this paper

• The Association Between Thromboembolic Events and ALK , ROS1 , RET Rearrangements or EGFR Mutations in Patients With Advanced Lung Adenocarcinoma: A Retrospective Cohort Study

  2025cites this paper
• Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors

  2025cites this paper
• Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay

  2025influential citation
• Ultra-fast eco-friendly UHPLC–MS/MS methodology for the quantification of ASP3026 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro metabolic incubation

  2025cites this paper
• Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report

  2025cites this paper
• Innovative green microwell spectrofluorometric assay with high sensitivity and throughput for the determination of ceritinib in capsules and plasma utilizing 4-fluoro-7-nitrobenzofurazan as a fluorogenic probe

  2025cites this paper
• Predictive Value of Peri-Coronary Fat Attenuation Index in Elderly Non-ST-Elevation Myocardial Infarction and Its Correlation with Platelet to Lymphocyte Ratio

  2025cites this paper
• Clinical characterization and therapeutic targeting of fusion genes in oncology

  2025cites this paper
• Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

  2025cites this paper
• An accurate DNA and RNA based targeted sequencing assay for clinical detection of gene fusions in solid tumors

  2025cites this paper
• Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges

  2025cites this paper
• NRG1 Fusions: The New Kid on the Block

  2025cites this paper
• Advancing edge-based clustering and graph embedding for biological network analysis: a case study in RASopathies

  2025cites this paper
• Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance

  2025cites this paper
• Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval

  2025cites this paper
• ALK in cancer: from function to therapeutic targeting

  2025cites this paper
• Inflammatory myofibroblastic tumors in children: clinical characteristics and treatment outcomes with a focus on targeted therapies.

  2025cites this paper
• RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

  2025cites this paper
• Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies

  2025cites this paper
• MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines

  2025cites this paper
• Reporting quality of dose-expansion cohorts in trials of anticancer drugs could be improved: a cross-sectional study

  2025cites this paper
• Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies—ALK and PIK3CA

  2024cites this paper
• Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis

  2024influential citation
• Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

  2024cites this paper
• Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

  2024cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

  2024cites this paper
• Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control

  2024cites this paper
• Enhancing Lung and Colon Cancer Detection Through Convolutional Neural Networks

  2024cites this paper
• Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

  2024influential citation
• Narrative review: precision medicine applications in neuroblastoma—current status and future prospects

  2024cites this paper
• Confirmation of Recurrent Lung Cancer Following Resection Using Liquid Biopsy, a Proof-of-Concept Real-World Study

  2024cites this paper
• Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

  2024cites this paper
• Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer

  2024cites this paper
• Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

  2024cites this paper
• Mitochondria of T Lymphocytes Promote Anti-Pulmonary Tumor Immune Response

  2024cites this paper
• MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

  2023cites this paper
• Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

  2023cites this paper
• Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds

  2023cites this paper
• Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

  2023cites this paper
• Clinical outcomes of ALK+ non-small cell lung cancer in Denmark

  2023cites this paper
• Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

  2023cites this paper
• Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

  2023cites this paper
• Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit

  2023cites this paper
• A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer

  2023cites this paper
• Mechanisms of cancer-associated thrombosis

  2023cites this paper
• EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries

  2023cites this paper
• Method development and validation of Ceritinib in bulk and pharmaceutical dosage form by UV spectrophotometry

  2023cites this paper
• Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non‐small cell lung cancer cells

  2023cites this paper
• Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors

  2023cites this paper
• Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

  2023cites this paper
• Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study

  2023cites this paper
• Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications

  2023cites this paper
• Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications

  2023cites this paper
• Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review

  2023cites this paper
• Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

  2022cites this paper
• ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

  2022cites this paper
• Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

  2022influential citation
• STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis

  2022cites this paper
• Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib

  2022cites this paper
• Immunotherapy and Biomarkers in Sarcoma

  2022cites this paper
• Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

  2022cites this paper
• Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations

  2022cites this paper
• Role of STK11 in ALK-positive non-small cell lung cancer

  2022cites this paper
• Signaling by ALK

  2022cites this paper
• Evolution of precision oncology-guided treatment paradigms.

  2022cites this paper
• Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

  2022cites this paper
• The coming decade in precision oncology: six riddles

  2022cites this paper
• Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption

  2022cites this paper
• Pharmacogenomics Driving Precision Cancer Medicine

  2022cites this paper
• Biomarkers in the management of lung cancer: changing the practice of thoracic oncology

  2022cites this paper
• QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads

  2022cites this paper
• Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

  2022cites this paper
• Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer

  2022cites this paper
• Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

  2022influential citation
• Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

  2022cites this paper
• Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction

  2022cites this paper
• Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

  2022cites this paper
• Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity

  2022cites this paper
• ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity

  2022cites this paper
• Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis

  2022cites this paper
• Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic

  2022cites this paper
• Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study

  2022cites this paper
• Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy

  2022cites this paper
• Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

  2022cites this paper
• The value of anticancer drugs — a regulatory view

  2021cites this paper
• Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

  2021cites this paper
• Implementing somatic mutation testing in clinical setting: recommendations from a panel of experts.

  2021cites this paper
• Development and Validation of Reverse Phase High Performance Liquid Chromatographic Method for Quantitative Estimation of Lenvatinib in Capsule Dosage Form

  2021cites this paper
• Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information

  2021cites this paper
• Highlights from the literature

  2021cites this paper
• 经3种ALK抑制剂及化疗治疗的1例非小细胞肺癌病例报道

  2021cites this paper
• Update on recent key publications in lung oncology: picking up speed

  2021cites this paper
• The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies

  2021cites this paper
• Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

  2021cites this paper
• Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview

  2021cites this paper
• Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

  2021cites this paper
• Molecular characteristics and clinical outcomes of complex ALK rearrangements identi ed by next- generation sequencing in non-small cell lung cancers

  2021cites this paper
• Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers

  2021cites this paper
• Paradigm shift in the management of metastatic nonsmall cell lung cancer

  2021cites this paper
• Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report

  2021cites this paper